

Parameter	Acceptable	Optimal
Indication	Adults at risk of invasive <i>S. aureus</i> infections	Adults at risk of invasive <i>S. aureus</i> infections and non-invasive disease, e.g., SSTI, pneumonia
Target Demographic	>65 yoa; pregnant women*	All ages, including pregnant women*
Presentation	Single-dose vial	Multi-dose vial
Dose Regimen	Two doses IM, one month apart	One dose IM
Human Dose	TBD	TBD
Safety Profile	Local or systemic side effects are equivalent to, or less than those for other vaccines	Local or systemic side effects are equivalent to, or less than those for other vaccines
Efficacy	>50%	>70%
Durability of Protection	One year; one month after birth*	Five years; three months after birth*
Coverage	>80% of globally clinically relevant <i>S. aureus</i> isolates including >90% drug-resistant strains	>90% of globally clinically relevant <i>S. aureus</i> isolates including >99% of drug-resistant strains
Stability	18 months at 2-8°C	Three years at 2-8°C
Contraindications	Some limitation of use associated with recent receipt of other vaccines	No prohibition of use in patients that have recently received other vaccines
Marketing Attributes	COGs acceptable for LMICs	Compatible with Essential Programme on Immunization, COGs acceptable for LMICs

*Maternal immunization indication, to protect against neonatal sepsis